gabapentin and Dizziness studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Dizziness: An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.

Research Excerpts

Excerpt	Relevance	Reference
"The goal of this study was to evaluate the efficacy and safety of gastroretentive gabapentin (G-GR) for the treatment of moderate-to-severe menopausal hot flashes."	9.19	Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause. ( Kagan, R; Pinkerton, JV; Portman, D; Sathyanarayana, R; Sweeney, M, 2014)
"This randomised, double-blind study compared the newer antiepileptic drugs (AEDs) gabapentin (GBP) and lamotrigine (LTG) as monotherapy in newly diagnosed epilepsy."	9.10	Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. ( Anhut, H; Brodie, MJ; Chadwick, DW; Garofalo, EA; Maton, S; Messmer, SL; Murray, G; Otte, A; Sauermann, W, 2002)
"The objective of this study was to compare the efficacy and tolerability of gabapentin and amitriptyline monotherapy in painful diabetic neuropathy."	9.09	Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. ( Buffa, C; Chiroli, S; Dallocchio, C; Mazzarello, P, 2000)
"In this pooled analysis of adverse-event data from 3 clinical trials in patients with PHN, the incidence of peripheral edema was increased when gabapentin was titrated to >or=1800 mg/d."	8.82	Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004)
"To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine."	8.81	Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002)
" The most frequently reported adverse events were dizziness (G-GR, 11%; placebo, 2%) and somnolence (G-GR, 5%; placebo, 3%)."	6.78	Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. ( Irving, GA; Rauck, RL; Sweeney, M; Vanhove, GF; Wallace, MS, 2013)
"Primary orthostatic tremor (OT) is a rare but disabling condition characterized by leg tremor and feelings of instability during stance."	6.72	Blinded placebo crossover study of gabapentin in primary orthostatic tremor. ( Byrnes, ML; Edwards, DJ; Mastaglia, FL; Rodrigues, JP; Stell, R; Thickbroom, GW; Walters, SE, 2006)
"Uremic pruritus is one of the most prevalent and bothersome dermatologic symptoms in patients with end-stage renal disease."	6.66	Gabapentin for uremic pruritus: a systematic review of randomized controlled trials. ( Castillo, RL; Dofitas, BL; Eusebio-Alpapara, KMV, 2020)
"Clonidine is a central alpha-2 agonist well known to produce a syndrome of bradycardia and hypotension in overdose."	5.62	"Road Rash" and Dizziness: A Case of Hemodynamically Significant Topical Clonidine Toxicity. ( Cumpston, KL; Downs, JW, 2021)
"Gabapentin is an effective treatment for chronic neuropathic pain but may cause dizziness, drowsiness, and confusion in some older adults."	5.27	Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population-based study. ( Burneo, J; Dev, VK; Dixon, SN; Fleet, JL; Garg, AX; Kuwornu, PJ; Montero-Odasso, M, 2018)
" She was injected with butylphthalide sodium chloride to improve nerve nutritional status and carbamazepine was prescribed to deal with prosopalgia and glossopharyngeal neuralgia."	5.22	Avellis syndrome with ipsilateral prosopalgia, glossopharyngeal neuralgia, and central post-stroke pain: A case report and literature review. ( Chen, Q; Gu, L; He, S; Jing, Z; Luo, K, 2022)
" Other outcomes were overall pain during well-defined mobilizations and at rest and sedation during the first 48 hours and from days 2-6, morphine use, anxiety, depression, sleep quality, and nausea, vomiting, dizziness, concentration difficulty, headache, visual disturbances, and adverse reactions."	5.20	Analgesic and sedative effects of perioperative gabapentin in total knee arthroplasty: a randomized, double-blind, placebo-controlled dose-finding study. ( Hansen, LT; Husted, H; Kehlet, H; Laursen, MB; Lunn, TH, 2015)
"The goal of this study was to evaluate the efficacy and safety of gastroretentive gabapentin (G-GR) for the treatment of moderate-to-severe menopausal hot flashes."	5.19	Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause. ( Kagan, R; Pinkerton, JV; Portman, D; Sathyanarayana, R; Sweeney, M, 2014)
" The following data were recorded: total daily pethidine and diclofenac consumption, numeric sedation score, and the postoperative nausea, vomiting, and dizziness scores."	5.19	Clinical study evaluating pregabalin efficacy and tolerability for pain management in patients undergoing laparoscopic cholecystectomy. ( Al Taher, WM; Bekawi, MS; El Wakeel, LM; Mageed, WM, 2014)
"This randomised, double-blind study compared the newer antiepileptic drugs (AEDs) gabapentin (GBP) and lamotrigine (LTG) as monotherapy in newly diagnosed epilepsy."	5.10	Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. ( Anhut, H; Brodie, MJ; Chadwick, DW; Garofalo, EA; Maton, S; Messmer, SL; Murray, G; Otte, A; Sauermann, W, 2002)
"The objective of this study was to compare the efficacy and tolerability of gabapentin and amitriptyline monotherapy in painful diabetic neuropathy."	5.09	Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. ( Buffa, C; Chiroli, S; Dallocchio, C; Mazzarello, P, 2000)
"Fifty patients with refractory partial seizures took part in a prospective, observational study of adjuvant gabapentin (GBP) in increasing doses."	5.08	High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients. ( Brodie, MJ; Forrest, G; Sills, GJ; Wilson, EA, 1998)
" On the other hand, patients with divalproex exhibited significantly higher risk of nausea compared to those with placebo, topiramate, propranolol, gabapentin and amitriptyline."	4.95	Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis. ( He, A; Li, C; Song, D; Zhang, L, 2017)
" The complications of vomiting, nausea, dizziness and pruritus were also compiled to assess the safety of gabapentin and pregabalin."	4.93	The efficacy of preoperative administration of gabapentin/pregabalin in improving pain after total hip arthroplasty: a meta-analysis. ( Ding, W; Mao, Y; Wu, L, 2016)
"In this pooled analysis of adverse-event data from 3 clinical trials in patients with PHN, the incidence of peripheral edema was increased when gabapentin was titrated to >or=1800 mg/d."	4.82	Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004)
"To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine."	4.81	Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002)
"Gabapentin (GBP) is a antiepileptic drug (AED) indicated as adjunct therapy for treatment of partial seizures, with and without secondary generalization, in patients 12 and older with epilepsy."	4.80	Gabapentin. ( Morris, GL, 1999)
"Thirty patients were enrolled: 10 on gabapentin, 10 on lamotrigine and 10 on carbamazepine monotherapy for epilepsy."	3.73	Measuring the effects of antiepileptic medications on balance in older people. ( Blum, D; Fife, TD; Fisher, RS, 2006)
"No significant pharmacokinetic interaction between the 2 drugs was seen in this study."	2.80	Gabapentin enacarbil and morphine administered in combination versus alone: a double-blind, randomized, pharmacokinetic, and tolerability comparison. ( Arumugham, T; Chen, C; Davy, M; Stier, B; Upward, J, 2015)
" The most frequently reported adverse events were dizziness (G-GR, 11%; placebo, 2%) and somnolence (G-GR, 5%; placebo, 3%)."	2.78	Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. ( Irving, GA; Rauck, RL; Sweeney, M; Vanhove, GF; Wallace, MS, 2013)
"Gabapentin is an anticonvulsant drug that has analgesic properties for acute postoperative pain."	2.74	The analgesic effect of gabapentin as a prophylactic anticonvulsant drug on postcraniotomy pain: a prospective randomized study. ( Aykac, B; Bingol, CA; Karlikaya, G; Sayin, M; Türe, H; Türe, U, 2009)
" XP13512 immediate-release (up to 2800 mg single dose and 2100 mg twice daily) was well absorbed (>68%, based on urinary recovery of gabapentin), converted rapidly to gabapentin, and provided dose-proportional exposure, whereas absorption of oral gabapentin declined with increasing doses to <27% at 1200 mg."	2.73	Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. ( Canafax, DM; Cundy, KC; Luo, W; Moors, TL; Sastry, S; Zou, J, 2008)
"Patient satisfaction with postoperative pain management at 24 h was better in gabapentin-treated patients [85."	2.72	Effect of oral gabapentin on postoperative epidural analgesia. ( Apfel, CC; Karamanlioglu, B; Kaya, G; Pamukçu, Z; Turan, A, 2006)
"Primary orthostatic tremor (OT) is a rare but disabling condition characterized by leg tremor and feelings of instability during stance."	2.72	Blinded placebo crossover study of gabapentin in primary orthostatic tremor. ( Byrnes, ML; Edwards, DJ; Mastaglia, FL; Rodrigues, JP; Stell, R; Thickbroom, GW; Walters, SE, 2006)
"Gabapentin doses >1,800 mg/day were as well tolerated as doses < or =1,800 mg/day and were not associated with more adverse events."	2.69	Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study. ( Bernstein, P; Faught, RE; Holmes, GL; Magnus-Miller, L; McLean, MJ; Morrell, MJ; Privitera, MD; Rose-Legatt, A; Willmore, LJ, 1999)
"The gabapentin dosage was titrated to effective tolerated dose up to 2400 mg/day."	2.69	Gabapentin as adjunctive therapy for partial seizures. ( Bruni, J, 1999)
" Results of outcome measures, including time to exit, completion rate, and mean time on monotherapy, showed no significant differences among dosage groups."	2.68	Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. ( Abou-Khalil, B; Beydoun, A; Cantrell, D; Fischer, J; Garofalo, E; Greiner, M; Harden, C; Hayes, A; Labar, DR; Pierce, M; Ramsay, RE; Sackellares, JC; Uthman, BM, 1997)
"Uremic pruritus is one of the most prevalent and bothersome dermatologic symptoms in patients with end-stage renal disease."	2.66	Gabapentin for uremic pruritus: a systematic review of randomized controlled trials. ( Castillo, RL; Dofitas, BL; Eusebio-Alpapara, KMV, 2020)
"A family history of orthostatic tremor was reported in 3/45 (7%) patients."	2.50	Orthostatic tremor: a review of 45 cases. ( Ondo, WG; Yaltho, TC, 2014)
"Gabapentinoids effectively reduce postoperative pain, opioid consumption, and opioid-related adverse effects after surgery."	2.44	Do surgical patients benefit from perioperative gabapentin/pregabalin? A systematic review of efficacy and safety. ( Hamunen, K; Kalso, E; Kontinen, VK; Tiippana, EM, 2007)
"Dizziness is not a unique clinical picture, but rather is the unspecific symptom of numerous diseases."	2.44	[Frequently occurring forms of dizziness and their treatment]. ( Thömke, F, 2007)
"Clonidine is a central alpha-2 agonist well known to produce a syndrome of bradycardia and hypotension in overdose."	1.62	"Road Rash" and Dizziness: A Case of Hemodynamically Significant Topical Clonidine Toxicity. ( Cumpston, KL; Downs, JW, 2021)
" A substantially lower median seizure frequency was observed at all gabapentin dosing periods (visit I - 2."	1.37	[Efficacy and tolerability of dose-escalation with generic gabapentin--a multicenter, non-interventional study]. ( Kaczyński, K; Lipa, A; Rejdak, K; Stelmasiak, Z, 2011)

Research

Studies (40)

Authors

Clinical Trials (21)

Trial Overview

Trial Outcomes

G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Week 24 of the Efficacy Treatment Period, Compared With Baseline.

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (12.50)	18.2507
2000's	17 (42.50)	29.6817
2010's	13 (32.50)	24.3611
2020's	5 (12.50)	2.80

Authors	Studies
He, S	1
Chen, Q	1
Jing, Z	1
Gu, L	1
Luo, K	1
Eusebio-Alpapara, KMV	1
Castillo, RL	1
Dofitas, BL	1
Shan, D	1
Zou, L	1
Liu, X	1
Shen, Y	1
Cai, Y	1
Zhang, J	1
Kharasch, ED	1
Clark, JD	1
Kheterpal, S	1
Downs, JW	1
Cumpston, KL	1
Androsova, G	1
Krause, R	1
Borghei, M	1
Wassenaar, M	1
Auce, P	1
Avbersek, A	1
Becker, F	1
Berghuis, B	1
Campbell, E	1
Coppola, A	1
Francis, B	1
Wolking, S	1
Cavalleri, GL	1
Craig, J	1
Delanty, N	1
Koeleman, BPC	1
Kunz, WS	1
Lerche, H	1
Marson, AG	1
Sander, JW	1
Sills, GJ	2
Striano, P	1
Zara, F	1
Sisodiya, SM	1
Depondt, C	1
Fleet, JL	1
Dixon, SN	1
Kuwornu, PJ	1
Dev, VK	1
Montero-Odasso, M	1
Burneo, J	1
Garg, AX	1
Pinkerton, JV	1
Kagan, R	1
Portman, D	1
Sathyanarayana, R	1
Sweeney, M	2
Bekawi, MS	1
El Wakeel, LM	1
Al Taher, WM	1
Mageed, WM	1
Yaltho, TC	1
Ondo, WG	1
Chen, C	1
Upward, J	1
Arumugham, T	1
Stier, B	1
Davy, M	1
Lunn, TH	1
Husted, H	1
Laursen, MB	1
Hansen, LT	1
Kehlet, H	1
Zhai, L	1
Song, Z	1
Liu, K	1
Mao, Y	1
Wu, L	1
Ding, W	1
He, A	1
Song, D	1
Zhang, L	1
Li, C	1
Cundy, KC	1
Sastry, S	1
Luo, W	1
Zou, J	1
Moors, TL	1
Canafax, DM	2
Kushida, CA	1
Becker, PM	1
Ellenbogen, AL	1
Barrett, RW	1
Türe, H	1
Sayin, M	1
Karlikaya, G	1
Bingol, CA	1
Aykac, B	1
Türe, U	1
Rejdak, K	1
Lipa, A	1
Kaczyński, K	1
Stelmasiak, Z	1
Rauck, RL	1
Irving, GA	1
Wallace, MS	1
Vanhove, GF	1
Sarkissian, A	1
Neher, JO	1
Singh, R	1
St Anna, L	1
Brodie, MJ	2
Chadwick, DW	1
Anhut, H	1
Otte, A	1
Messmer, SL	1
Maton, S	1
Sauermann, W	1
Murray, G	1
Garofalo, EA	1
Foldvary-Schaefer, N	1
De Leon Sanchez, I	1
Karafa, M	1
Mascha, E	1
Dinner, D	1
Morris, HH	1
Burchell, BJ	1
Spira, PJ	1
Beran, RG	1
Dierking, G	1
Duedahl, TH	1
Rasmussen, ML	1
Fomsgaard, JS	1
Møiniche, S	1
Rømsing, J	1
Dahl, JB	1
Parsons, B	1
Tive, L	1
Huang, S	1
Turan, A	1
Kaya, G	1
Karamanlioglu, B	1
Pamukçu, Z	1
Apfel, CC	1
Rodrigues, JP	1
Edwards, DJ	1
Walters, SE	1
Byrnes, ML	1
Thickbroom, GW	1
Stell, R	1
Mastaglia, FL	1
Fife, TD	1
Blum, D	1
Fisher, RS	1
Tiippana, EM	1
Hamunen, K	1
Kontinen, VK	1
Kalso, E	1
Thömke, F	1
Beydoun, A	1
Fischer, J	1
Labar, DR	1
Harden, C	1
Cantrell, D	1
Uthman, BM	1
Sackellares, JC	1
Abou-Khalil, B	1
Ramsay, RE	1
Hayes, A	1
Greiner, M	1
Garofalo, E	1
Pierce, M	1
Wilson, EA	1
Forrest, G	1
McLean, MJ	1
Morrell, MJ	1
Willmore, LJ	1
Privitera, MD	1
Faught, RE	1
Holmes, GL	1
Magnus-Miller, L	1
Bernstein, P	1
Rose-Legatt, A	1
Bruni, J	1
Morris, GL	1
Dallocchio, C	1
Buffa, C	1
Mazzarello, P	1
Chiroli, S	1
Hurley, SC	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Cognitive Changes Associated With Initiation of Gabapentin Treatment in Adults With Chronic Pain[NCT04106011]		3 participants (Actual)	Observational	2020-01-10	Terminated (stopped due to PI request - low enrollment)
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER_ Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women[NCT01080300]	Phase 3	600 participants (Actual)	Interventional	2010-08-31	Completed
A Double-Blind, 3-Part Crossover Study to Assess the Pharmacokinetics and Tolerability of Single Doses of Gabapentin Enacarbil and Morphine Administered Alone and in Combination in Healthy Subjects[NCT01476124]	Phase 1	18 participants (Actual)	Interventional	2011-08-31	Completed
Randomized Prospective Study Comparing Variable Gabapentin Dosages for Postoperative Analgesia Following Open Thoracotomy[NCT05172570]	Phase 3	120 participants (Anticipated)	Interventional	2021-04-06	Recruiting
"Preoperative Gabapentin and Its Effects on Postoperative Analgesia in Patients Undergoing Cosmetic Breast Surgery"[NCT05997355]		100 participants (Anticipated)	Interventional	2023-09-01	Not yet recruiting
Gabapentin Regimens and Their Effects on Opioid Consumption[NCT03334903]	Phase 4	77 participants (Actual)	Interventional	2018-05-15	Completed
A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epileps[NCT00438451]	Phase 4	361 participants (Actual)	Interventional	2007-01-31	Completed
The Efficacy of Gabapentine and Splint Therapy in Bruxers: a Randomized Clinical Trial[NCT01255878]		20 participants (Actual)	Interventional	2010-03-31	Completed
Acute Effects of Gabapentin on Polysomnography Parameters and on Hypothalamic-pituitary-adrenal, Hypothalamic-pituitary-gonadal and Somatotropic Axes During Sleep in Older Men: a Randomized, Double-blind, Placebo-controlled Trial[NCT02599701]	Phase 4	8 participants (Actual)	Interventional	2015-09-30	Terminated (stopped due to Gabapentin increased hypopnea-apnea index in the first 8 recruited subjects.)
Impact of Gabapentin on Slow Wave Sleep in Adult Critically Ill Patient.[NCT04818450]		60 participants (Actual)	Interventional	2021-04-19	Completed
The Effect of Neurontin on Pain Management in the Acutely Burned Patient[NCT01265056]		53 participants (Actual)	Interventional	2010-02-28	Completed
Effects of Preoperative Gabapentin Versus Pregabalin on Shoulder Pain After Laparoscopic Cholecystectomy. A Randomized Clinical Trial[NCT03241875]	Phase 4	90 participants (Actual)	Interventional	2016-12-01	Completed
The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair[NCT02419443]	Phase 4	100 participants (Anticipated)	Interventional	2011-08-31	Active, not recruiting
Pregabalin for the Treatment of Pain After Posterior Spinal Fusions.[NCT01366196]		86 participants (Actual)	Interventional	2008-10-31	Completed
Effect of Preoperative Pregabalin on Propofol Induction Dose[NCT01158859]	Phase 4	50 participants (Anticipated)	Interventional	2010-04-30	Completed
Perioperative Administration of Pregabalin in Laparoscopic Living Donor Nephrectomy (L-LDN) - an Adjuvance to Peroral Analgetic Treatment - a Randomized Controlled Study[NCT01059331]	Phase 4	80 participants (Actual)	Interventional	2010-02-28	Completed
Gabapentin as a Pre-emptive Analgesic in Oral and Maxillofacial Surgical Procedures[NCT02957097]	Phase 4	0 participants (Actual)	Interventional	2019-09-30	Withdrawn (stopped due to Original PI left institution and the PI who took over was not able to initiate the study so it was never started.)
The Effect of Gabapentin on Acute Pain and PONV in Bariatric Surgical Patients[NCT00886236]		62 participants (Actual)	Interventional	2008-02-29	Completed
Pre-Emptive Analgesia in Ano-Rectal Surgery[NCT02402543]		90 participants (Actual)	Interventional	2014-06-30	Completed
Single Dose Preoperative Gabapentin Use in Minimally Invasive Hysterectomy for Acute Pain Management[NCT02703259]	Phase 4	137 participants (Actual)	Interventional	2016-06-30	Completed
Effect of Gabapentin on Postoperative Opioid Analgesic Use and Pain in Adolescents Undergoing Tonsillectomy[NCT05024825]	Phase 4	17 participants (Actual)	Interventional	2017-08-04	Terminated (stopped due to recruitment target not met.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily frequency of moderate to severe hot flashes in post menopausal women at Week 24 of the efficacy treatment period compared with Baseline. (NCT01080300)
Timeframe: Baseline, Week 24

G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Severity Score of Moderate to Severe Hot Flashes at Week 24 of the Efficacy Treatment Period, Compared With Baseline.

Intervention	hot flashes (Least Squares Mean)
G-ER 1800 mg	-8.99
Sugar Pill	-7.91

"G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily severity score of moderate to severe hot flashes in post menopausal women (score defined as Mild (1), Moderate (2), and Severe (3)) at Week 24 of the efficacy treatment period compared with Baseline." (NCT01080300)
Timeframe: Baseline, Week 24

Change From Baseline to Weeks 4, Week 12, and Week 24 in Average Daily Sleep Interference Score.

Intervention	scores on a scale (Least Squares Mean)
G-ER 1800 mg	-0.86
Sugar Pill	-0.64

Sleep Interference Score Range: Minimum value = 0, maximum value = 10 Lower scores indicate better outcome (ie, less interference) (NCT01080300)
Timeframe: Baseline, Week 4, Week 12, and Week 24

Changes From Baseline in Quality of Life Scores, Measured by the Menopause-Specific Quality of Life Questionnaire (MENQOL) to Weeks, 4, 12, 24 of the Efficacy Treatment Period.

Intervention	units on a scale (Least Squares Mean)
	Change from Baseline to Week 4: LOCF daily rating	Change from Baseline to Week 12: LOCF daily rating	Change from Baseline to Week 24: LOCF daily rating
G-ER 1800 mg	-2.67	-3.09	-3.15
Sugar Pill	-1.31	-2.17	-2.20

"4 sub-categories each scored individually: Minimum value = 1, maximum value = 8.~Overall summary score was mean of the 4 sub-category scores (minimum = 1 and maximum = 8).~Lower scores indicate better outcome (ie, less severity)" (NCT01080300)
Timeframe: Baseline, Week 4, Week 12, and Week 24

Changes From Baseline in Sleep Quality Scores, Measured by the Insomnia Severity Index (ISI) to Week 4, Week 12, and Week 24 of the Efficacy Treatment Period.

Intervention	scores on a scale (Least Squares Mean)
	Baseline LOCF MENQOL score at Week 4	Baseline LOCF MENQOL score at Week 12	Baseline LOCF MENQOL score at Week 24
G-ER 1800 mg	-0.91	-1.01	-1.01
Sugar Pill	-0.71	-0.87	-0.96

Insomnia Severity Index (ISI) scored on 4-point Likert-scales ('0' not at all - '4' extremely) for 7 sub-categories. Final score is sum of each sub-category generating a total sleep quality score (0-28). Minimum value = 0, maximum value = 28 (Lower scores indicate better outcome (ie, less severity)). (NCT01080300)
Timeframe: Baseline, Week 4, Week 12, and Week 24

Clinical Global Impression of Change (CGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period.

Intervention	scores on a scale (Least Squares Mean)
	Change from Baseline to Week 4: LOCF ISI rating	Change from Baseline to Week 12: LOCF ISI rating	Change from Baseline to Week 24: LOCF ISI rating
G-ER 1800 mg	-6.47	-7.02	-6.71
Sugar Pill	-4.13	-5.17	-4.95

"Proportion of patients who were categorized as very much or much improved in CGIC at Week 12 and Week 24. Scale range is 6 categories: minimum value = very much worse to maximum value = very much improved." (NCT01080300)
Timeframe: Week 12 and Week 24

G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline.

Intervention	Participants (Count of Participants)
	Baseline LOCF Proportion at Week 12	Baseline LOCF Proportion at Week 24
G-ER 1800 mg	173	159
Sugar Pill	122	124

G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily frequency of moderate to severe hot flashes in post menopausal women at Week 4 of the efficacy treatment period compared with Baseline and at Week 12 of the efficacy treatment period compared with Baseline. (NCT01080300)
Timeframe: Baseline, Week 4, and Week 12

G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Severity Score of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline.

Intervention	hot flashes (Least Squares Mean)
	Baseline LOCF Average Daily Frequency at Week 4	Baseline LOCF Average Daily Frequency at Week 12
G-ER 1800 mg	-6.72	-7.64
Sugar Pill	-5.01	-6.50

"G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily severity score of moderate to severe hot flashes in post menopausal women (score defined as Mild (1), Moderate (2), and Severe (3)) at Week 4 of the efficacy treatment period compared with Baseline and at Week 12 of the efficacy treatment period compared with Baseline." (NCT01080300)
Timeframe: Baseline, Week 4, and Week 12

Patient Global Impression of Change (PGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period.

Intervention	scores on a scale (Least Squares Mean)
	Baseline LOCF Average Daily Severity at Week 4	Baseline LOCF Average Daily Severity at Week 12
G-ER 1800 mg	-0.42	-0.65
Sugar Pill	-0.22	-0.46

"Proportion of patients who were categorized as very much or much improved for PGIC at Week 12 and Week 24. Scale range is 6 categories: minimum value = very much worse to maximum value = very much improved." (NCT01080300)
Timeframe: Week 12 and Week 24

Percent of Patients With 75% or Greater Reduction in Average Daily Frequency of Moderate to Severe Hot Flashes

Percent of Patients With 75% or Greater Reduction in Average Daily Severity Score of Moderate to Severe Hot Flashes

Safety of G-ER Measuring Columbia-Suicide Severity Rating Scale (C-SSRS).

Intervention	Participants (Count of Participants)
	Baseline LOCF Proportion at Week 12	Baseline LOCF Proportion at Week 24
G-ER 1800 mg	173	156
Sugar Pill	130	114

Intervention	Participants (Count of Participants)
	Baseline LOCF Proportion at Week 12	Baseline LOCF Proportion at Week 24
G-ER 1800 mg	125	146
Sugar Pill	101	122

Intervention	Participants (Count of Participants)
	Baseline LOCF Average Daily Score at Week 12	Baseline LOCF Average Daily Score at Week 24
G-ER 1800 mg	48	62
Sugar Pill	36	48

"Columbia-Suicide Severity Rating Scale (C-SSRS). Subjects were classified as 0=no suicidal ideation or 1=suicidal ideation. Outcome Measure is number of participants with or without suicidal ideation.~Higher counts without suicidal ideation = better outcome." (NCT01080300)
Timeframe: Week 4, Week 12, Week 24/Early Termination, Week 28

"VAS Score 1: How Much Pain do You Feel in Your Operative Site When Resting?"

Intervention	Participants (Count of Participants)
	Patients Taking C-SSRS at Week 472302449	Patients Taking C-SSRS at Week 472302448	Patients Taking C-SSRS at Week 1272302448	Patients Taking C-SSRS at Week 1272302449	Patients Taking C-SSRS at Week 24/EarlyTermination72302448	Patients Taking C-SSRS at Week 24/EarlyTermination72302449	Patients Taking C-SSRS at Week 2872302448	Patients Taking C-SSRS at Week 2872302449
	Without Suicidal Ideation	With Suicidal Ideation
Gabapentin Extended Release	260
Placebo	257
Placebo	0
Gabapentin Extended Release	224
Placebo	215
Gabapentin Extended Release	0
Placebo	1
Gabapentin Extended Release	271
Placebo	266
Gabapentin Extended Release	1
Gabapentin Extended Release	256
Placebo	243

Surgical site pain. Scale 0-10, with 0 best and 10 worst (NCT03334903)
Timeframe: 2-3 months after surgery (at 2nd postoperative appointment)

"VAS Score 2: How Much Pain do You Feel in Your Operative Site When Moving?"

Intervention	score on 10-point scale (Mean)
Standard of Care	2.26
Postoperative Gabapentin Regimen	2.46

Surgical site pain. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

"VAS Score 3: How Well Are You Sleeping?"

Intervention	score on a 10-point scale (Mean)
Standard of Care	3.84
Postoperative Gabapentin Regimen	3.54

Sleep quality. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

"VAS Score 4: How Bad is Your Nausea?"

Intervention	score on a 10-point scale (Mean)
Standard of Care	5.73
Postoperative Gabapentin Regimen	6.38

Nausea. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

"VAS Score 5: How Satisfied Are You With Your Pain Management?"

Intervention	score on a 10-point scale (Mean)
Standard of Care	0.36
Postoperative Gabapentin Regimen	0.17

Satisfaction. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Days Taking Opioids

Intervention	score on a 10-point scale (Mean)
Standard of Care	7.83
Postoperative Gabapentin Regimen	8.48

Number of days until patients are finished consuming opioid medications after discharge. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Opioid Consumption

Intervention	days (Mean)
Standard of Care	14.8
Postoperative Gabapentin Regimen	18.7

Mean opioid consumption, measured in mg of morphine equivalents. (NCT03334903)
Timeframe: 2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).

58-week Retention Rate Measured by the Number of Drop Outs Due to Adverse Events or Seizures From Day 1 of Treatment

Percentage of Patients Remaining Seizure Free at Week 58 (Visit 6)

Intervention	morphine equivalents (Mean)
Standard of Care	287.0
Postoperative Gabapentin Regimen	281.1

Intervention	proportion of participants (Mean)
Levetiracetam	0.61
Carbamazepine	0.46
Lamotrigine	0.56

Percentage of patients experiencing no seizures until week 58 (Visit 6) and did not discontinue the study until week 58. (NCT00438451)
Timeframe: week 58

Percentage of Patients Remaining Seizure-free at Week 30 (Visit 4)

Intervention	percentage of participants (Number)
Levetiracetam	43
Carbamazepine	33
Lamotrigine	38

Percentage of patients experiencing no seizures until week 30 (Visit 4) and did not discontinue the study until week 30. (NCT00438451)
Timeframe: Week 30

Proportion of Seizure-free Days During the Maintenance Phase for Subjects Who Enter the Maintenance Phase

Results of Cognitive Testing (EpiTrack© by UCB) - Score at V6

Intervention	percentage of participants (Number)
Levetiracetam	48
Carbamazepine	39
Lamotrigine	49

Intervention	proportion of seizure-free days (Number)
Levetiracetam	0.99
Carbamazepine	0.99
Lamotrigine	0.99

EPITrack-Score shows the performance of attention and executive functions. Higher values indicate a better performance. The results of EPITrack Score ranges between 7 and 45. (NCT00438451)
Timeframe: week 58

The Absolute Seizure Frequency During the Maintenance Phase (Weeks 7 - 58)

Intervention	units on a scale (Mean)
Levetiracetam	26.0
Carbamazepine	26.0
Lamotrigine	25.4

"Seizure frequency was assessed by investigators in the CRF at the Visits V3, V4, V5 and V6.~The absolute seizure frequency during the maintenance phase was defined as the sum of those entries." (NCT00438451)
Timeframe: over 52 weeks

The Time (in Days) to First Break-through Seizure (From Day 1 of Treatment)

Time to Drop Out

Intervention	number of seizures (Number)
Levetiracetam	168
Carbamazepine	131
Lamotrigine	130

Intervention	days (Median)
Levetiracetam	NA
Carbamazepine	NA
Lamotrigine	NA

number of days between randomization and premature discontinuation of the study (NCT00438451)
Timeframe: 58 weeks

Portland Neurotoxicity Scale (PNS) at V6

Intervention	days (Median)
Levetiracetam	NA
Carbamazepine	265
Lamotrigine	NA

"The PNS is a 15-item scale. Each item can be scored from 1 to 9. There are a total score (includes all items, range:15 to 135) and two subscores: The cognitive toxicity subscore (10 items: Energy Level, Memory, Interest, Concentration, Forgetfulness, Sleepliness, Moodiness, Alertness, Attention Span, Motivation, range:10 to 90) and the somatomoto subscore (5 items: Vision, Walking, Coordination, Tremor, Speech, range:5-45). The score is calculated by taking the mean of all non-missing values times the number of items.~Lower values indicate better quality of life." (NCT00438451)
Timeframe: at week 58

QOLIE-31 (Quality Of Life In Epilepsy) Results at V6

Intervention	units on a scale (Mean)
	Cognitive toxicity subscore	Somatomotor subscore	Total Score
Carbamazepine	27.3	11.4	38.7
Lamotrigine	23.7	10.8	34.5
Levetiracetam	22.2	10.5	32.7

The QOLIE-31 is a 31 item score that measures the quality of life in epilepsy (each item with a range of 0 to 100). There are 7 sub-scores seizure worry (items 11,21,22,23,25), overall quality of life (items 1,14), emotional well-being (items 3,4,5,7,9), energy/fatigue (items 2,6,8,10), cognitive functioning (items 12,15,16,17,18,26), medication effects (items 24,29,30) and social functioning (13,19,20,27,28). These scores were combined to a total score by Total score = seizure worry*0.08 + overall quality of life*0.14 + emotional well-being*0.15 + energy/fatigue*0.12 + cognitive functioning*0.27 + medication effects*0.03 + social functioning*0.21 For all scores, higher values indicate better quality of life. Each score has a possible range from 0 to 100. (NCT00438451)
Timeframe: 58 weeks, final visit

Results of Cognitive Testing (EpiTrack© by UCB) - Categories at V6

Intervention	units on a scale (Mean)
	Seizure worry	Overall quality of life	Emotional well-being	Energy/fatigue	Cognitive functioning	Medication effects	Social functioning	Total Score	Health Scale
Carbamazepine	75.4	65.0	69.8	54.5	68.9	70.6	76.3	68.9	65.7
Lamotrigine	75.0	67.1	67.4	59.8	68.0	72.6	76.7	69.1	67.5
Levetiracetam	85.1	67.2	72.0	60.8	75.1	77.6	81.1	73.9	69.5

"Evaluation of current testing at V6:~≥29 score points: Inconspicuous; 26 to 28 score points: Borderline;~≤25 score points: Impaired" (NCT00438451)
Timeframe: 58 weeks

Results of Cognitive Testing (EpiTrack© by UCB) - Changes to Baseline (V0) at Week 58 (V6)

Intervention	participants (Number)
	Without pathological findings	Borderline	Impaired
Carbamazepine	34	17	33
Lamotrigine	31	15	39
Levetiracetam	38	10	36

"Evaluation of Changes~Changes in the EpiTrack® Score were categorized as follows:~≥5 score points: Improved;~-3 to 4 score points: Unchanged;~≤-4 score points: Worsened" (NCT00438451)
Timeframe: week 58

Difference in Psychological Outcomes on the Sickness Inventory Profile (SIP)

Intervention	participants (Number)
	Improved	Unchanged	Worsened
Carbamazepine	16	56	8
Lamotrigine	15	53	13
Levetiracetam	15	61	6

The sickness inventory profile (SIP) is a behaviorally based measure of health status. Scores range from 0-68 with higher numbers indicating worse outcomes. The study report total SIP score. The higher the score the worse the function. (NCT01265056)
Timeframe: First Clinic Follow Up After Discharge

Opioid Consumption Between the Treatment and the Control Groups (Morphine Equivalents)

Intervention	units on a scale (Mean)
Placebo	34.9
Gabapentin	36.0

(NCT01265056)
Timeframe: From time of enrollment to 2 weeks after being discharged

Psychological Functioning as Evaluated by the Brief Symptom Inventory (BSI) Between Treatment and Placebo Groups

Intervention	morphine equivalents (Mean)
Placebo	7.0
Gabapentin	6.7

The Brief Symptom Inventory 18 (BSI 18) is designed with reliability in mind. The BSI 18 assessment gathers patient-reported data to help measure psychological distress and psychiatric disorders in medical and community populations. As the latest in an integrated series of test instruments that include the SCL-90-R®, BSI® (53 questions), and DPRS® instruments, the BSI 18 test offers a more effective, easy-to-administer tool to help support clinical decision-making and monitor progress throughout treatment. BSI-18 measures three dimensions with 6 questions a piece (somatization , depression , anxiety) and overall psychological distress scores (Global severity index, GSI). Each of the 18 items range from a score of 0-4; total score ranges from 0-72 with higher scores indicating worse function. The GSI score is calculated as the mean of the three subscales. The study reported the GSI score. Higher score is worse. (NCT01265056)
Timeframe: First Clinic Follow Up After Discharge

Numerical Pain Rating Scale Score on Day of Surgery

Intervention	units on a scale (Mean)
Placebo	9
Gabapentin	7.3

Pain scores based on a scale of 0 to 10 with 0 being no pain and 10 being the worst pain imaginable. (NCT01366196)
Timeframe: Day of Surgery

Numerical Pain Rating Scale Score on Postoperative Day 1 at Rest

Intervention	units on a scale (Mean)
Control Group (C)	3.8
Pregabalin Group (P)	2.9

Pain scores based on a scale of 0 to 10 with 0 being no pain and 10 being the worst pain imaginable. (NCT01366196)
Timeframe: Postoperative Day 1 at rest

Numerical Pain Rating Scale Score With Physical Therapy on Postoperative Day 1

Intervention	units on a scale (Mean)
Control Group (C)	3.7
Pregabalin Group (P)	3.3

Pain scores based on a scale of 0 to 10 with 0 being no pain and 10 being the worst pain imaginable. (NCT01366196)
Timeframe: Postoperative Day 1 with Physical Therapy

Oral Analgesic Supplementation Use

Intervention	units on a scale (Mean)
Control Group (C)	4.3
Pregabalin Group (P)	4.5

Tabulate number of patients that used supplemental oral analgesics (NCT01366196)
Timeframe: Day of surgery

Patient Controlled Analgesia (PCA) Hydromorphone Usage

Evaluate Incidence of Respiratory Depression as Evidenced by Pulse Oximetry Data

Evaluate the Amount of Diluadid Given Postoperatively

Intervention	Participants (Count of Participants)
Control Group (C)	25
Pregabalin Group (P)	21

Intervention	mL (Mean)
Control Group (C)	44
Pregabalin Group (P)	39

Intervention	% oxygen saturation (Mean)
1 Preoperative Gabapentin Liquid	93
2 Preoperative and Postoperative Gabapentin Liquid	94
3 Preoperative and Postoperative Placebo Liquid	95

The amount of intraoperative and postoperative opioids used will be collected and analyzed for the three different arms. (NCT00886236)
Timeframe: 120 hours

Number of Participants Who Experience Incidence of Postoperative Nausea.

Narcotic Use at 2 Weeks Postop

Intervention	ml (Mean)
1 Preoperative Gabapentin Liquid	11.035
2 Preoperative and Postoperative Gabapentin Liquid	8.7
3 Preoperative and Postoperative Placebo Liquid	12.4

Intervention	Participants (Count of Participants)
1 Preoperative Gabapentin Liquid	12
2 Preoperative and Postoperative Gabapentin Liquid	11
3 Preoperative and Postoperative Placebo Liquid	12

Assessment of the amount of narcotic use postoperatively at 2 weeks. will use opioid equivalence table to convert all narcotic use to oxycodone equivalents (NCT02703259)
Timeframe: 2 weeks

Narcotic Use at 24 Hours Postop

Intervention	morphine milligram equivalents (Mean)
Gabapentin	167.2
Control	187.3

Assessment of the amount of narcotic use postoperatively at 24 hours. will use opioid equivalence table to convert all narcotic use to oxycodone equivalents (NCT02703259)
Timeframe: 24 hours

Subjective Pain at 2 Weeks Postop

Intervention	morphine milligram equivalents (Mean)
Gabapentin	158.8
Control	175.0

"Assessment of the subject pain score postoperatively at 2 weeks. will use a numeric analog scale from 0-10.~The pain scale ranging from 0-10 with 0 representing No Pain and 10 representing the Worst Pain Possible" (NCT02703259)
Timeframe: 2 weeks

Subjective Pain at 24 Hours Postoperative

Intervention	score on a scale (Mean)
Gabapentin	1.3
Control	1.4

Pain score assesses patient subjective pain via patient reported numeric analogue scale, range 0-10 with 0 being no pain and 10 being severe pain. (NCT02703259)
Timeframe: 24 hours

Number of Patient With Gabapentin Adverse Effects at 2 Weeks Postoperatively

Intervention	score on a scale (Mean)
Gabapentin	3.4
Control	3.4

Will assess for known symptoms of gabapentin postoperatively at 2 weeks. We will survey subjects regarding their experience of the following symptoms: dizziness/drowsiness, fatigue, loss of balance, blurry vision, tremulousness, swelling, nausea, vomiting, diarrhea, and allergic reaction (NCT02703259)
Timeframe: 2 weeks

Number of Patient With Gabapentin Adverse Effects at 24 Hours Postoperatively

Will assess for known symptoms of gabapentin postoperatively at 24 hours. We will survey subjects regarding their experience of the following symptoms: dizziness/drowsiness, fatigue, loss of balance, blurry vision, tremulousness, swelling, nausea, vomiting, diarrhea, and allergic reaction (NCT02703259)
Timeframe: 24 hours

Intervention	Participants (Count of Participants)
	Dizziness	Blurred vision	Somnolence	Difficulty walking	Tremulousness	Nausea	Vomiting
Control	8	3	21	5	2	7	1
Gabapentin	12	4	18	5	4	12	0

Article	Year
Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population-based study. PloS one, 2018, Volume: 13, Issue:3 Topics: Aged; Aged, 80 and over; Amines; Confusion; Cyclohexanecarboxylic Acids; Disease-Free Survival; Dizz	2018
Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause. Menopause (New York, N.Y.), 2014, Volume: 21, Issue:6 Topics: Adult; Aged; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Delayed-Action Preparati	2014
Clinical study evaluating pregabalin efficacy and tolerability for pain management in patients undergoing laparoscopic cholecystectomy. The Clinical journal of pain, 2014, Volume: 30, Issue:11 Topics: Adult; Amines; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Cholecystectomy, Laparoscopic; C	2014
Gabapentin enacarbil and morphine administered in combination versus alone: a double-blind, randomized, pharmacokinetic, and tolerability comparison. Clinical therapeutics, 2015, Feb-01, Volume: 37, Issue:2 Topics: Adult; Amines; Analgesics, Opioid; Carbamates; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dizz	2015
Analgesic and sedative effects of perioperative gabapentin in total knee arthroplasty: a randomized, double-blind, placebo-controlled dose-finding study. Pain, 2015, Volume: 156, Issue:12 Topics: Aged; Aged, 80 and over; Amines; Analgesics; Analgesics, Opioid; Arthroplasty, Replacement, Knee; Cy	2015
Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. Journal of clinical pharmacology, 2008, Volume: 48, Issue:12 Topics: Adult; Aged; Amines; Area Under Curve; Biological Availability; Capsules; Carbamates; Cross-Over Stu	2008
Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology, 2009, Feb-03, Volume: 72, Issue:5 Topics: Adult; Amines; Anti-Anxiety Agents; Carbamates; Central Nervous System; Cyclohexanecarboxylic Acids;	2009
The analgesic effect of gabapentin as a prophylactic anticonvulsant drug on postcraniotomy pain: a prospective randomized study. Anesthesia and analgesia, 2009, Volume: 109, Issue:5 Topics: Administration, Oral; Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid;	2009
Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. Journal of pain and symptom management, 2013, Volume: 46, Issue:2 Topics: Amines; Analgesics; Causality; Comorbidity; Cyclohexanecarboxylic Acids; Disorders of Excessive Somn	2013
Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia, 2002, Volume: 43, Issue:9 Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Asthenia; Clinical Protocols; Cyclohexan	2002
Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology, 2003, Dec-23, Volume: 61, Issue:12 Topics: Acetates; Adolescent; Adult; Aged; Amines; Analgesics; Anticonvulsants; Ataxia; Chronic Disease; Cro	2003
Effects of gabapentin on postoperative morphine consumption and pain after abdominal hysterectomy: a randomized, double-blind trial. Acta anaesthesiologica Scandinavica, 2004, Volume: 48, Issue:3 Topics: Acetates; Adult; Aged; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Cycloh	2004
Effects of gabapentin on postoperative morphine consumption and pain after abdominal hysterectomy: a randomized, double-blind trial. Acta anaesthesiologica Scandinavica, 2004, Volume: 48, Issue:3 Topics: Acetates; Adult; Aged; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Cycloh	2004
Effects of gabapentin on postoperative morphine consumption and pain after abdominal hysterectomy: a randomized, double-blind trial. Acta anaesthesiologica Scandinavica, 2004, Volume: 48, Issue:3 Topics: Acetates; Adult; Aged; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Cycloh	2004
Effects of gabapentin on postoperative morphine consumption and pain after abdominal hysterectomy: a randomized, double-blind trial. Acta anaesthesiologica Scandinavica, 2004, Volume: 48, Issue:3 Topics: Acetates; Adult; Aged; Amines; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Cycloh	2004
Effect of oral gabapentin on postoperative epidural analgesia. British journal of anaesthesia, 2006, Volume: 96, Issue:2 Topics: Acetaminophen; Administration, Oral; Adult; Aged; Amines; Analgesia, Epidural; Analgesia, Patient-Co	2006
Blinded placebo crossover study of gabapentin in primary orthostatic tremor. Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:7 Topics: Aged; Amines; Antiparkinson Agents; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dizziness; Doub	2006
Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. Neurology, 1997, Volume: 49, Issue:3 Topics: Acetates; Adolescent; Adult; Ambulatory Care; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecar	1997
High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients. Epilepsy research, 1998, Volume: 29, Issue:2 Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Diarrhea; D	1998
Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study. Epilepsia, 1999, Volume: 40, Issue:7 Topics: Acetates; Adolescent; Adult; Ambulatory Care; Amines; Anticonvulsants; Asthenia; Carbamazepine; Cycl	1999
Gabapentin as adjunctive therapy for partial seizures. Epilepsia, 1999, Volume: 40 Suppl 6 Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dizziness; Dru	1999
Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. Journal of pain and symptom management, 2000, Volume: 20, Issue:4 Topics: Acetates; Aged; Aged, 80 and over; Amines; Amitriptyline; Analgesics; Ataxia; Cyclohexanecarboxylic	2000

Article	Year
Perioperative Gabapentinoids: Deflating the Bubble. Anesthesiology, 2020, Volume: 133, Issue:2 Topics: Analgesics; Ataxia; Dizziness; Gabapentin; Humans; Pain, Postoperative; Pregabalin; Preoperative Car	2020
"Road Rash" and Dizziness: A Case of Hemodynamically Significant Topical Clonidine Toxicity. Military medicine, 2021, 02-26, Volume: 186, Issue:3-4 Topics: Adult; Clonidine; Dizziness; Drug Compounding; Exanthema; Gabapentin; Humans; Male	2021
Comparative effectiveness of antiepileptic drugs in patients with mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia, 2017, Volume: 58, Issue:10 Topics: Adolescent; Adult; Aged; Amines; Anticonvulsants; Ataxia; Benzodiazepines; Carbamazepine; Clobazam;	2017
[Efficacy and tolerability of dose-escalation with generic gabapentin--a multicenter, non-interventional study]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2011, Volume: 64, Issue:2 Topics: Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Disorders of Excessive Somnolence; Dizz	2011
Gabapentin increases slow-wave sleep in normal adults. Epilepsia, 2002, Volume: 43, Issue:12 Topics: Acetates; Adult; Amines; Anticonvulsants; Arousal; Cyclohexanecarboxylic Acids; Dizziness; Dose-Resp	2002
Gabapentin increases slow-wave sleep in normal adults. Epilepsia, 2002, Volume: 43, Issue:12 Topics: Acetates; Adult; Amines; Anticonvulsants; Arousal; Cyclohexanecarboxylic Acids; Dizziness; Dose-Resp	2002
Gabapentin increases slow-wave sleep in normal adults. Epilepsia, 2002, Volume: 43, Issue:12 Topics: Acetates; Adult; Amines; Anticonvulsants; Arousal; Cyclohexanecarboxylic Acids; Dizziness; Dose-Resp	2002
Gabapentin increases slow-wave sleep in normal adults. Epilepsia, 2002, Volume: 43, Issue:12 Topics: Acetates; Adult; Amines; Anticonvulsants; Arousal; Cyclohexanecarboxylic Acids; Dizziness; Dose-Resp	2002
Gabapentin increases slow-wave sleep in normal adults. Epilepsia, 2002, Volume: 43, Issue:12 Topics: Acetates; Adult; Amines; Anticonvulsants; Arousal; Cyclohexanecarboxylic Acids; Dizziness; Dose-Resp	2002
Gabapentin increases slow-wave sleep in normal adults. Epilepsia, 2002, Volume: 43, Issue:12 Topics: Acetates; Adult; Amines; Anticonvulsants; Arousal; Cyclohexanecarboxylic Acids; Dizziness; Dose-Resp	2002
Gabapentin increases slow-wave sleep in normal adults. Epilepsia, 2002, Volume: 43, Issue:12 Topics: Acetates; Adult; Amines; Anticonvulsants; Arousal; Cyclohexanecarboxylic Acids; Dizziness; Dose-Resp	2002
Gabapentin increases slow-wave sleep in normal adults. Epilepsia, 2002, Volume: 43, Issue:12 Topics: Acetates; Adult; Amines; Anticonvulsants; Arousal; Cyclohexanecarboxylic Acids; Dizziness; Dose-Resp	2002
Gabapentin increases slow-wave sleep in normal adults. Epilepsia, 2002, Volume: 43, Issue:12 Topics: Acetates; Adult; Amines; Anticonvulsants; Arousal; Cyclohexanecarboxylic Acids; Dizziness; Dose-Resp	2002
Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology, 2003, May-13, Volume: 60, Issue:9 Topics: Acetates; Amines; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dizziness; Double-Blind Method; G	2003
Measuring the effects of antiepileptic medications on balance in older people. Epilepsy research, 2006, Volume: 70, Issue:2-3 Topics: Aged; Amines; Anticonvulsants; Ataxia; Carbamazepine; Cyclohexanecarboxylic Acids; Dizziness; Epilep	2006
Valproate and other anticonvulsants for psychiatric disorders. The Medical letter on drugs and therapeutics, 2000, Dec-11, Volume: 42, Issue:1094 Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Bipolar	2000

gabapentin and Dizziness